Rafael (RFL) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Rafael (RFL) over the past year, gaining 268.7% versus a gain of 9.6%. Over five years, RLYB leads with a -86.3% price change compared with -95.1% for RFL. Rallybio is the larger company by market cap ($90.4 million vs $83.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RFL | RLYB |
|---|---|---|
| Share price | $1.60 | $17.02 |
| Market cap | $83.20M | $90.42M |
| 1-day change | +8.11% | +0.18% |
| YTD return | +25.42% | +209.58% |
| 1-year return | +9.63% | +268.71% |
| 5-year return | -95.09% | -86.32% |
| P/E ratio (TTM) | — | 2.12 |
| EPS (TTM) | $-0.72 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.96 | $17.57 |
| 52-week low | $1.12 | $3.67 |
| Distance from 52-week high | -59.60% | -3.15% |
| Average volume | 159.84K | 21.33K |
| Shares outstanding | 51.21M | 5.31M |
| Employees | 21 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed RFL by 259.1 percentage points over the past year.
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
RFL vs RLYB FAQ
Which is bigger, Rafael or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $90.42M compared with $83.20M for Rafael (RFL).
Which stock has performed better over the past year, RFL or RLYB?
RLYB returned +268.71% over the past 12 months, compared with +9.63% for RFL (price return, excluding dividends). Past performance does not predict future results.
Are Rafael and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.